-
Most Popular
Search Results
240 results for dgse
FDA Win Sends Celsion Corporation (CLSN) Shares Higher
Celsion (CLSN) shares were up Thursday as the company received FDA clearance on its plans to start a Phase I/II clinical trial of OVATION II.
Pfizer’s Covid-19 Vaccine Delay Isn’t Welcome News for Shareholders
The UK’s chief medical officers want to delay second doses of the Pfizer/BioNTech vaccine. Is this much ado about nothing for PFE stock?
3 Healthcare Stocks for Retirement Investors
Medical costs keep on rising. For investors in retirement, a dose of healthcare stocks could be the key to dealing with those costs.
With the European Union Buying Doses, Novavax Has Plenty of Upside Left
Novavax secured a supply agreement with the European Union, which is a sign of confidence for its vaccine. NVAX stock could move higher from here.
UnitedHealth Group Inc Stock Requires Big Dose of Caution
UNH stock has been on a tear but there are long term issues with the company.
Real Goods Solar, Inc. (RGSE) Stock Skyrockets on Dow Deal
Real Goods Solar (RGSE) stock was skyrocketing today following news of a deal with Dow (DWDP) concerning solar shingles.
Bristol-Myers Squibb Co (BMY) Suffers Heavy Dose of Disappointment
BMY stock — at around $49 — is now fairly valued. But given its failure rate, waiting for Bristol-Myers to get to “cheap” is the…
Lowe’s Companies, Inc.: Get a Dose of Relative Strength With LOW Stock
Lowe’s (LOW) stock tenaciously held support even during the broader market weakness in late August. Now, investors can ride a build in relative strength.
Pfizer to Sell Vaccine to Poor Countries for Fraction of Price
Pfizer has agreed to sell its vaccine Prevnar 13 to poor countries for a fraction of the price. The vaccine will be sold for $3.50…
Why Southwest Airlines Co, AT&T Inc., and General Motors Company Are Today’s 3 Worst Stocks
A healthy dose of skepticism, as well as some poor financial results and lowered forecasts, drove these three names lower on Thursday.
Ignore the Naysayers and Invest in Novavax Stock
NVAX stock boasts one of the strongest long-term cases in the biotech industry despite being criticized by the press.
2 Emerging Market Dividend ETFs for Adventurous Investors
Valuations for emerging markets are tantalizingly inexpensive and the darkest dividend clouds may have already passed. For the adventurous, here are some ideas to consider…
Why Cara Therapeutics Inc (CARA) Stock Is Plunging Today
Cara Therapeutics (CARA) stock was hit hard on Friday following poor results in its Phase 2b trial of osteoarthritis oral drug CR845.
Trade of the Day: Arrowhead Research (ARWR)
ARWR has a potentially revolutionary product here by most standards.
Why Is uniQure (QURE) Stock Up 51% Today?
UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s disease treatment candidate.
Moderna Stock Looks Like a Winner as the Covid-19 Vaccine Race Loosens
Moderna looks like it has a winner with its Covid-19 vaccine. MRNA stock could make $35 billion if it delivers 1 billion doses, making its…
Why Moderna Has More Upside Than Its Covid-19 Vaccine Implies
The wild volatility in Moderna stock before and after its vaccine approval is coming to an end but its long-term prospects are on the way…
Marijuana News: Teva Pharmaceuticals Industries Ltd (ADR) Signs Cannabis Inhaler Deal
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) has some good marijuana news for those living in Israel that want to inhale the drug.
Moderna Has Huge Growth Potential As Its Covid-19 Trials Wrap Up
Phase 3 trials for Moderna’s coronavirus vaccine candidate could mean $37 billion in revenue for MRNA stock if mRNA-1273 wins approval.
Novavax Has Growth Potential Both Now and After the Pandemic
Novavax has a Covid-19 vaccine already in production. With a world that still needs billions of doses, NVAX stock is positioned for growth.
2 – 10 of 240 results
